Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Maker Biomet Builds Second Production Base In China

This article was originally published in PharmAsia News

Executive Summary

U.S.-based medical device manufacturer Biomet recently began construction of its second production base in Changzhou High-tech District. The new facility will mainly produce orthopedic implants. Biomet aims to build up the $15 million production base to become China's medical device manufacturing center. Identifying the medical device industry as a key sector, Changzhou High-tech District has congregated a group of device makers such as Kanghui Medical Innovation, Trauson (Jiangsu) Medical Instrument and Orthmed Medical Instrument. The district will also set up a quality platform to accept international industrial capital transfers and boost the region's economic development. (Click here for more - Chinese Language)

You may also be interested in...



Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials

Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.

Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069122

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel